For more information, please visit find the company on LinkedIn or Twitter. Additionally, Day One Biopharmaceuticals Inc scored a 83 in the Healthcare sector, ranking it higher than 83 of stocks in that sector. DAWN received an overall rating of 96, which means that it scores higher than 96 of stocks. Day One is based in Brisbane, California. Day One Biopharmaceuticals Inc is around the top of the Healthcare sector according to InvestorsObserver. The Company’s pipeline also includes pimasertib, an investigational, oral, highly-selective small molecule inhibitor of mitogen‐activated protein kinases 1 and 2 (MEK-1/-2). Overview Stock Screener Earnings Calendar Sectors Nasdaq DAWN U.S.: Nasdaq Day One Biopharmaceuticals Inc. ![]() The Company’s lead product candidate, tovorafenib, is an investigational, oral, brain-penetrant, highly-selective type II pan-RAF kinase inhibitor. Day One aims to re-envision cancer drug development and redefine what’s possible for all people living with cancer-regardless of age-starting from Day One.ĭay One partners with leading clinical oncologists, families, and scientists to identify, acquire, and develop important emerging cancer treatments. The Company’s name was inspired by “The Day One Talk” that physicians have with patients and their families about an initial cancer diagnosis and treatment plan. Day One was founded to address a critical unmet need: the dire lack of therapeutic development in pediatric cancer. We put kids first and are developing targeted therapies that deliver to their needs. Public Company Edition: The stock market has been unkind to biotech firms but investors rewarded some drug developers for clinical trial successes. An archived replay of the webcast will be available for 30 days following the live presentation.ĭay One Biopharmaceuticals is a clinical-stage biopharmaceutical company that believes when it comes to pediatric cancer, we can do better. ![]() ![]() PT.Ī live audio webcast of the discussion will be available by visiting the Events & Presentations section of the Company’s website. BRISBANE, Calif., (GLOBE NEWSWIRE) - Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced management will participate in a fireside chat at the Goldman Sachs 44 th Annual Global Healthcare Conference on Wednesday, June 14 at 11:20 a.m.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |